No matter which biopharmaceutical pipeline analysis you read, one thing is for certain: Oncology dominates. Companies have been built, sold, and failed based on trying to improve the therapy options cancer patients have at their disposal.
The terminal nature of the disease and the lack of multiple, equally effective treatments results in a business model where high-priced treatments abound. Combine this with epidemiological factors (a relatively high proportion of us will get cancer) and it is no wonder the oncology landscape has many highly motivated players.
While this is not groundbreaking news to our industry, stating it out loud sets a base from which to have discussions around how the landscape of Oncology sales/ information strategies are changing and their effects on physicians and pharmaceutical companies.
The purpose of this report is to measure several aspects of how pharmaceutical companies could and should interact with Oncologists. ISR surveyed 102 Oncologists to determine how they prefer to receive certain types of drug information from pharmaceutical and biotechnology manufacturers.
What You'll Learn:
- How US Oncologists want to receive drug info from pharma/biotech manufacturers and which information they find most valuable
- MSLs, sales reps, eDetailing, peer-based literature, payer reps?
- Does practice type make a difference?
- Benchmark how much time your reps and MSLs spend with Oncologists vs. the industry average
- Prescribing power Oncologists will have in the near future
- The most valuable MSL traits and which pharma companies have the best MSLs
1. Access to Oncologists
2. Frequency and duration of visits
3. Impact and satisfaction with interactions
4. The MSL interaction environment
5. Preferred information dissemination vehicles
6. Prescribing trends
7. Practice setting analysis
8. Study data
Purchasers of this report have also purchased:
Effectiveness of communication channels…
… to deliver specific types of information to Oncologists…
… across different study/data types
In the News:
08/03/2012 - Pharmaceutical Executive - "The Increasing Value of Medical Science Liaisons"